Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 599

1.

Behavioral effects of current Alzheimer's disease treatments: a descriptive review.

Cummings JL, Mackell J, Kaufer D.

Alzheimers Dement. 2008 Jan;4(1):49-60. doi: 10.1016/j.jalz.2007.10.011. Review.

PMID:
18631950
[PubMed - indexed for MEDLINE]
2.

Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.

Rodda J, Morgan S, Walker Z.

Int Psychogeriatr. 2009 Oct;21(5):813-24. doi: 10.1017/S1041610209990354. Epub 2009 Jun 19. Review.

PMID:
19538824
[PubMed - indexed for MEDLINE]
3.

Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.

Beier MT.

Pharmacotherapy. 2007 Mar;27(3):399-411. Review.

PMID:
17316151
[PubMed - indexed for MEDLINE]
4.

Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease.

Finkel SI.

Clin Ther. 2004 Jul;26(7):980-90. Review.

PMID:
15336465
[PubMed - indexed for MEDLINE]
5.

Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.

Tariot PN.

J Clin Psychiatry. 2006;67 Suppl 3:15-22; quiz 23. Review.

PMID:
16649847
[PubMed - indexed for MEDLINE]
6.

Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders.

Cummings JL, McRae T, Zhang R; Donepezil-Sertraline Study Group.

Am J Geriatr Psychiatry. 2006 Jul;14(7):605-12.

PMID:
16816014
[PubMed - indexed for MEDLINE]
7.

Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer's disease.

Grossberg GT, Pejović V, Miller ML, Graham SM.

Dement Geriatr Cogn Disord. 2009;27(2):164-72. doi: 10.1159/000200013. Epub 2009 Feb 5. Review.

PMID:
19194105
[PubMed - indexed for MEDLINE]
8.

Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.

Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT; Memantine MEM-MD-12 Study Group.

Curr Alzheimer Res. 2008 Feb;5(1):83-9.

PMID:
18288936
[PubMed - indexed for MEDLINE]
9.

Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study.

Cummings JL, Koumaras B, Chen M, Mirski D; Rivastigmine Nursing Home Study Team.

Am J Geriatr Pharmacother. 2005 Sep;3(3):137-48.

PMID:
16257816
[PubMed - indexed for MEDLINE]
10.

Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis.

Gauthier S, Loft H, Cummings J.

Int J Geriatr Psychiatry. 2008 May;23(5):537-45.

PMID:
18058838
[PubMed - indexed for MEDLINE]
11.

Atypical antipsychotics for the treatment of dementia-related behaviors: an update.

Daiello LA.

Med Health R I. 2007 Jun;90(6):191-4.

PMID:
17633594
[PubMed - indexed for MEDLINE]
12.

Pharmacotherapeutic approaches to the treatment of Alzheimer's disease.

Standridge JB.

Clin Ther. 2004 May;26(5):615-30. Review.

PMID:
15220008
[PubMed - indexed for MEDLINE]
13.

Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis.

Maidment ID, Fox CG, Boustani M, Rodriguez J, Brown RC, Katona CL.

Ann Pharmacother. 2008 Jan;42(1):32-8. Epub 2007 Dec 4.

PMID:
18056833
[PubMed - indexed for MEDLINE]
14.

Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies.

Gauthier S, Wirth Y, Möbius HJ.

Int J Geriatr Psychiatry. 2005 May;20(5):459-64.

PMID:
15852444
[PubMed - indexed for MEDLINE]
15.

The use of cognitive enhancers in behavioral disturbances of Alzheimer's disease.

Miller LJ.

Consult Pharm. 2007 Sep;22(9):754-62. Review.

PMID:
18198970
[PubMed - indexed for MEDLINE]
16.

Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies.

Wilcock GK, Ballard CG, Cooper JA, Loft H.

J Clin Psychiatry. 2008 Mar;69(3):341-8.

PMID:
18294023
[PubMed - indexed for MEDLINE]
17.

Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.

Riepe MW, Adler G, Ibach B, Weinkauf B, Tracik F, Gunay I.

Dement Geriatr Cogn Disord. 2007;23(5):301-6. Epub 2007 Mar 13.

PMID:
17356273
[PubMed - indexed for MEDLINE]
18.

Caregiver-specific outcomes in antidementia clinical drug trials: a systematic review and meta-analysis.

Lingler JH, Martire LM, Schulz R.

J Am Geriatr Soc. 2005 Jun;53(6):983-90. Review.

PMID:
15935021
[PubMed - indexed for MEDLINE]
19.

Effectiveness of open-label donepezil treatment in patients with Alzheimer's disease discontinuing memantine monotherapy.

Sakka P, Tsolaki M, Hort J, Hager K, Soininen H, López Pousa S, Li C, Schwam E.

Curr Med Res Opin. 2007 Dec;23(12):3153-65.

PMID:
17988434
[PubMed - indexed for MEDLINE]
20.

Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.

Cumbo E, Ligori LD.

J Alzheimers Dis. 2014;39(3):477-85. doi: 10.3233/JAD-131190.

PMID:
24164733
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk